A clinical trial of hydroxychloroquine for the treatment of hospitalized adults with COVID-19 has been halted after the drug was found to be ineffective, the National Institutes of Health (NIH) announced on Friday.

According to the NIH's press release, the drug poses "no harm" to those who have taken it, but has still been deemed "very unlikely to be beneficial" to those being treated for coronavirus.

The study aimed to enroll "more than 500 adults who are currently hospitalized with COVID-19," and had enrolled more than 470 patients before it was halted, according to the NIH.

Advertisement

Though hydroxychloroquine is typically used to treat malaria and rheumatoid conditions like arthritis, according to the NIH, it had been tested to treat COVID-19 because "the drug had demonstrated antiviral activity, an ability to modify the activity of the immune system."

In recent months, hydroxychloroquine has been provided to a wide range of people across the US including 1,300 veterans infected with COVID-19.

"I take it," he said at the time. "I would've told you that three, four days ago, but we never had a chance because you never asked me the question."

More recently at the start of June, White House physician Sean Conley confirmed in a memo that Trump had been prescribed hydroxychloroquine, zinc, and vitamin D, for a two-week period. The note also stated that Trump "remains healthy" with "no findings of significance or changes to report" from his annual physical, as Business Insider's Grace Panetta previously reported.

See the rest here:
A clinical trial of hydroxychloroquine has been halted after the drug was deemed 'very unlikely to be benefici - Business Insider India

Comments are closed.